

# Index

## A

Acetyl-CoA carboxylase (ACC), 247  
Acid-labile subunit (ALS), 75, 267  
Adiponectin, 47  
Aging and cancer  
  balancing factors, 33  
  carcinogenesis, 27  
  dietary restriction, 29  
  IGFs, 32–33  
  molecular aetiology  
    gene mutations, 25  
    lung cancer, 26  
    PI3k–Akt/PKB pathway, 27  
  neoplastic lesions, 28  
  ocult tumours and clinical cancers  
    autopsy, 29  
    breast cancer, 31  
    genetic risk, 31–32  
    neoplastic lesions, 29–30  
    prostate cancer, 30  
    sporadic cancers, 31  
  rats, 28  
Alveolar rhabdomyosarcoma (ARMS),  
  148–149  
AMG479, 202–203  
Androgen-independent (AI) disease, 85  
Androgen receptors (AR), 85, 160  
Ataxia-telangiectasia mutated (ATM), 223  
Autopsy, 29  
AVE1642, 201–202

## B

Benzimidazoles, 219–220  
BIIB022, 203

Body mass index (BMI), 37

## BRCA1

  breast and ovarian cancer, 164  
  immunohistochemical analysis,  
    165  
  prostate cancer, 166  
Breast cancer, 27  
  aging, 31  
  cytotoxic and hormonal therapy, 73  
  diagnosis, 73  
  gene signatures, 78–79  
  IGF-I and IGFBP-3, 123–125  
  IGF ligands and bindings proteins  
    angiogenic factor, 76  
    postmenopausal women, 75–76  
    tumor cell growth, 76–77  
  IGF-1R expression and adaptor proteins,  
    77–78  
  IGF signaling, 74–75  
  IGF targeting, 79  
  indirect evidence, 15  
  meta-analysis, 126  
  obesity, 14  
  resistance, 78  
  risk factor, 123  
  serologic evidence  
    blood donation, 16  
    EPIC study, 16  
    estrogen receptor, 17  
    IGFBP-3 and risk, 17–18  
    insulin/C-peptide, 18  
    meta-analyses, 17  
    premenopausal and postmenopausal,  
      15–16  
  targeted therapy, 73–74

**C**

- Calorie restriction (CR)
  - animal model, 232
  - anticancer effects, 232–234
  - cancer
    - epidemiological evidence of, 234–235
    - experimental evidence of, 235–236
  - chronic diseases, 231
  - cytokines, 237
  - energy balance-related hormones, 237–238
  - estrogen receptor, 236
  - leptin, 237
  - metabolic hormones, 237
  - mimetics, 238–239
- Cancer
  - adipocytokines, 53–54
  - adipose tissue and insulin resistance
    - adiponectin, 47
    - interleukin-6, 45–46
    - leptin, 47
    - resistin, 46
    - tumor necrosis factor alpha, 45
  - aging (*see* Aging and cancer)
  - breast cancer (*see* Breast cancer)
  - calorie restriction (*see* Calorie restriction (CR))
  - estrogen, 54–55
  - hyperglycemia and, 50–51
  - and hyperinsulinemia, 48–50
  - hyperlipidemia and, 51–53
  - insulin analogues, 55–56
  - insulin resistance, 44–45
  - insulin signaling, 42–44
  - metformin, 56–58
  - obesity, 39–40, 42, 54–55
  - prostate cancer (*see* prostate cancer)
  - thiazolidinediones, 58–59
  - type 2 diabetes, 40–42
- Cancer cell metabolism
  - amino acid metabolism and, 250–251
  - AMPK and, 247–249
  - fatty acid metabolism, 249–250
  - glucose uptake rates, 251–253
  - hyperinsulinemia, 245, 246
  - obesity, 245, 246
  - oncogenes and tumor suppressor genes, 253–254
  - pharmaceuticals targeting
    - AMPK activators, 255–256
    - antimetabolite chemotherapy, 254–255
    - central carbon metabolism, 257
    - lipogenesis inhibitors, 256–257

- type II diabetes, 245, 246
  - Warburg effect, 251–253
- Castrate-resistant prostate cancer (CRPC), 96
- Catechols, 221–222
- Chronic myeloid leukemia (CML), 221
- Colorectal cancer (CRC), 27, 126–128
  - indirect evidence, 5
  - serologic evidence
    - IGFBP-3 and risk, 8
    - IGF-1 concentrations, 6
    - insulin/C-peptide, 8–9
    - risk factors, 6–7
- Cyclin-dependent kinases (CDKs), 109

**D**

- Dihydrotestosterone (DHT), 86

**E**

- Electrophoretic mobility shift assays (EMSA), 164
- Embryonal rhabdomyosarcoma (ERMS), 148–149
- Endoplasmic reticulum (ER), 111
- Epidermal growth factor (EGF), 78
- Epidermal growth factor receptor (EGFR), 204
- Epithelial ovarian cancer (EOC), 78–79
- Epithelial-to-mesenchymal transition (EMT), 182
- Estrogen, 54–55
- Estrogen receptors (ER), 17, 160, 236
- Estrogen receptor-signaling pathway, 205
- European Prospective Investigation into Cancer and Nutrition (EPIC), 7, 16, 40, 76, 123, 129
- Ewing's sarcoma family of tumors (ESFT), 149–150

**F**

- Fatty acids (FAs), 247
- Focal adhesion kinase (FAK), 109
- Forkhead transcription factors (FOXO), 106
- Free fatty acid (FFA), 44, 249

**G**

- Gastrointestinal stromal tumor (GIST), 151
- Glitazones. *See* Thiazolidinediones
- Glycine-*N*-methyltransferase (GNMT), 251
- Glycogen synthase kinase 3 (GSK3), 106
- Growth hormone (GH), 264

**H**

- Heat shock proteins (HSPs), 227
- Hormonal therapy, 224–225
- Human umbilical vein endothelial cells (HUVECs), 109

**I**

- IMC-A12, 202
- Imidazopyrazines, 218–219
- Inhibitor of apoptosis (IAP), 94
- Insulin and IGFs signaling specificity
  - cancer patients
    - atypical IGF-IR and IRs, 271
    - autocrine and paracrine production, 267, 269
    - hyperinsulinemia, 272
    - IR-A/IGF-IR hybrids, 271
    - IR/IGF-IR hybrids formation, 269–270
    - reduced M6P/IGF-IIR expression, 269
    - unbalanced IR-A, 270
  - molecular bases
    - intracellular substrates and biological effects, 266
    - IR isoforms and tissue-specific distribution, 265
    - ligand bioavailability, 266–267
    - tissue-specific IR, 264–265
  - molecular mechanisms, 264
  - unbalanced intracellular signaling
    - insulin resistant patients, 273–274
    - IR isoform balance and cell differentiation, 273
    - mitogenesis and migration, 272–273
- Insulin degrading enzyme (IDE), 94–95
- Insulin-like growth factor I (IGF-1)
  - calorie restriction (*see* Calorie restriction (CR))
  - deficiency
    - A2058 cells, 114
    - Akt, 107
    - angiogenesis, 119–120
    - anti-IGF-IR antibodies, 130
    - breast cancer, 123–126
    - calcineurin/NFAT pathway, 108
    - calorie-restriction, 122
    - cancer cell lines, 114–115
    - canonical and noncanonical signaling pathways, 106, 107
    - caveoli, 109
    - CDKs, 109–110
    - cell adhesion, 116–118
    - colorectal cancer, 126–128
    - cytoskeletal arrangements, 115–116
    - folding process, 111–112
    - GH/IGF-1 axis, 129, 130
    - lung tumors, 121
    - MAPK pathway, 107–108
    - molecular chaperones, 112–113
    - mTORC1, 106–107
    - paxillin activation, 116
    - p53 gene, 110
    - prostate cancer, 128–129
    - PTEN, 111
    - Rho family, 113–114
    - RTK family, 106
    - tissue remodeling, 118–119
    - TKI, 130
    - WT1, 110–111
    - XBP-1 protein, 112
  - epidemiologic evidence
    - breast cancer, 14–18
    - colorectal cancer, 5–9
    - IGFBP-3 level, 4–5
    - prostate cancer, 9–14
  - physiology and mechanism
    - IGF system, 2
    - insulin, 2, 3
    - level, determinants of, 4
    - receptor signaling, 2–3
- Insulin-like growth factor-I receptor (IGF-IR)
  - acquired tumor resistance mechanisms, 207
  - AKT activation, 206
  - AMG479, 202–203
  - animal models, 196–198
  - animal tumor models, 181, 182
  - anti-IGF-IR antibody-targeting strategies, 195–196
  - AVE1642, 201–202
  - BIIB022, 203
  - cancer therapies
    - chemotherapy, 222
    - ErbB family-targeted therapies, 223–224
    - hormonal therapy, 224–225
    - radiation therapy, 223
  - chemotherapy, 204
  - clinical trials, 198, 199
  - Cre recombinase, 180
  - CT domain, 193–194
  - cysteine-rich region, 193
  - disruption
    - liver, 187
    - pancreas, 185–186
    - prostate cancer, 186–187
  - drug sensitivity, 227
  - embryonic stem cells, 179–180

- Insulin-like growth factor-I receptor (IGF-IR)  
*(cont.)*  
 estrogen receptor-signaling pathway, 205  
 gene expression  
   androgen receptor signaling pathway, 169–170  
   breast and ovarian cancer, 164  
   disrupted transcription factors, 168  
   estrogen receptor signaling pathways, 168–169  
   immunohistochemical analysis, 165  
   KLF, 161, 162  
   MCF-7, 163  
   MS, 162, 163  
   multiple tumor suppressors, 170–171  
   p53, 166–167  
   potential epigenetic regulation, 171–172  
   prostate cancer, 166  
   renal cancer, 167  
   role, 159  
   tumors, 160–161  
 hemizygotes, 180  
 human testing, 198  
 IGF-1R ATP-competitive inhibitors  
   benzimidazoles, 219–220  
   imidazopyrazines, 218–219  
   pyrrolopyrimidines, 216–218  
   pyrrolotriazines, 220–221  
   2,4,6-triaminopyrimidine, 221  
 IGF-1R/IR pathway, 225–226  
 IMC-A12, 202  
 LKB/AMP kinase pathway, 206–207  
 lung, 184–185  
 mammary gland  
   CD8-IGFIR transgenic mice, 181, 182  
   developmental stage, 184  
   kras gene, 183  
   MTB-IGFIR transgenic mice, 182–183  
   trastuzumab-resistant tumors, 184  
 MK0646, 200–201  
 NSCLC patients, 200  
 R1507, 201  
 rtTA, 180–181  
 salivary gland, 187–188  
 SCH717454, 201  
 signaling pathways, 226  
 SiRNA, 207  
 small-molecule IGF-1R inhibitors, 216  
 substrate inhibitors  
   catechols, 221–222  
   picropodophyllotoxin, 222  
 tamoxifen, 205  
 toxicity, 204  
 tumor xenograft growth, 204–205  
 tyrosine kinase activity, 194–195  
 VEGF receptor activation, 206  
 Insulin receptor substrates (IRSs), 106  
 Interleukin-6, 45–46
- K**  
 Krüppel-like factor-6 (KLF6), 162
- L**  
 Leiomyosarcoma, 147  
 Leptin, 47  
 Liver IGF-1 deficient (LID), 121  
 Loss of heterozygosity (LOH), 149  
 Loss of imprinting (LOI), 149  
 Lung cancer, 26
- M**  
 Mass spectrometry (MS), 162  
 Metformin, 56–58  
 Mitogen-activated protein kinase (MAPK), 106, 147  
 MK0646, 200–201  
 Monoacylglycerol lipase (MAGL), 250  
 Mouse mammary tumor virus (MMTV), 121, 182
- N**  
 Nonsmall cell lung carcinoma (NSCLC), 74, 197  
 Nordihydroguaiaretic acid (NDGA), 221  
 Nuclear factor of activated T cells (NFAT), 108  
 Nuclear receptors  
   androgen receptor signaling pathway, 169–170  
   estrogen receptor signaling pathways, 168–169
- O**  
 Obesity  
   adipocytokines, 53–54  
   adipose tissue and insulin resistance  
     adiponectin, 47  
     interleukin-6, 45–46  
     leptin, 47  
     resistin, 46  
     tumor necrosis factor alpha, 45  
   breast cancer, 14

- and cancer, 39–40, 54–55
  - estrogen, 54–55
  - hyperglycemia and cancer, 50–51
  - hyperinsulinemia and cancer, 48–50
  - hyperlipidemia and cancer, 51–53
  - insulin resistance, 44–45
  - insulin signaling, 42–44
    - and type 2 diabetes, 38–39, 42
  - Osteosarcoma, 150
- P**
- Pediatric preclinical testing program (PPTP), 152
  - Pediatric sarcomas
    - clinical trials, 153–155
    - ESFT, 149–150
    - GIST, 151
    - IGF-1R antibody therapy, 152–153
    - IGF signaling pathway, 147–148
    - mTOR inhibitors, 153
    - osteosarcoma, 150
    - preclinical models, 152
    - rhabdomyosarcoma, 148–149
    - RMS xenograft growth, 152
    - synovial sarcomas, 151
    - TKIs, 152
  - Phosphatase and tensin homolog (PTEN), 111
  - Phosphofruktokinase2 (PFK2), 253
  - Phosphoinositide-dependent kinase 1 (PDK1), 106
  - Phosphoinositide-3-kinase (PI3K), 106
  - Phosphotyrosine-binding (PTB), 43
  - Picropodophyllin (PPP), 114, 183
  - Picropodophyllotoxin (PPP), 222
  - Platelet-derived growth factor receptor alpha (PDGFRA), 151
  - Positron emission tomography (PET), 252
  - Postmenopausal breast cancer, 15–16
  - Prostate cancer, 128–129
    - aging, 30
    - AI disease, 85
    - carcinogenesis
      - castration resistant cells, 97
      - cixutumumab, 98
      - figitumumab therapy, 98
      - IGFBP-3 levels, 96
    - castration, 87–88
    - dihydrotestosterone, 87
    - IAP, 94
    - IGF-IR
      - androgen modulation, 90
      - AR phosphorylation, 90–91
      - AR signaling, 94–95
      - cell transformation, 89
      - inhibitor androgen synthesis, 86–87
      - nuclear translocation, 91–93
    - indirect evidence, 10
    - insulin receptor substrate-1 (IRS-1), 93–94
    - potential interaction, 88–89
    - serologic evidence
      - advanced and nonadvanced prostate cancer, 12
      - diagnostic marker, 13
      - IGF-1 and risk, 11
      - IGFBP-3, 13
      - insulin and C-peptide levels, 13–14
      - low/high-grade, 12
  - Prostate carcinogenesis
    - castration resistant cells, 97
    - cixutumumab, 98
    - figitumumab therapy, 98
    - IGFBP-3 levels, 96
  - Prostate-specific antigen (PSA), 29
  - Prostatic intraepithelial neoplasia (PIN), 247
  - Pyrolopyrimidines, 216–218
  - Pyrolotriazines, 220–221
- R**
- R1507, 201
  - Radiation therapy, 223
  - Receptor tyrosine kinases (RTKs), 106, 233, 250
  - Resistin, 46
  - Reverse tetracycline transactivator (rtTA), 180
  - Rhabdomyosarcoma (RMS), 148–149
- S**
- Sarcosine, 251
  - SCH717454, 201
  - Sex hormone binding globulin (SHBG), 49
  - Src homology collagen (SHC), 107
  - Synovial sarcomas, 151
- T**
- Tamoxifen, 205
  - TATA-binding protein (TBP), 166
  - Tetracycline response element (TRE), 181
  - Thiazolidinediones, 58–59
  - 2,4,6-Triaminopyrimidine, 221
  - Tuberous sclerosis complex (TSC), 234
  - Tumor necrosis factor- $\alpha$ , 45

## Type 2 diabetes

- adipose tissue and insulin resistance
  - adiponectin, 47
  - interleukin-6, 45–46
  - leptin, 47
  - resistin, 46
  - tumor necrosis factor alpha, 45
- cancer, 40–41
  - hyperglycemia, 50–51
  - hyperinsulinemia, 48–50
  - hyperlipidemia, 51–53
- insulin analogues, 55–56
- insulin resistance, 44–45
- insulin signaling, 42–44
- metformin, 56–58
- obesity, 38–39, 42
- thiazolidinediones, 58–59

- Tyrosine kinase inhibitors (TKIs), 130, 152, 216

**V**

- Vascular endothelial growth factor (VEGF), 119, 193, 206
- von-Hippel Lindau gene (VHL), 111, 160

**W**

- Wilms tumor protein 1 (WT1), 110, 160
- Wiskott–Aldrich syndrome protein (WASP), 114

**X**

- X-box-binding protein-1 (XBP-1), 112